Korea’s KHIDI, AstraZeneca Ink MOU For Oncology Research
This article was originally published in PharmAsia News
AstraZeneca inks a memorandum of understanding with Korea’s Health Industry Development Institute for oncology research.
You may also be interested in...
SEOUL - A string of deals during the past five years with five multinational companies - Pfizer, Sanofi-Aventis, AstraZeneca, Novartis and Japan's Otsuka Pharmaceuticals - have boosted South Korea's status as a leading destination for global clinical trials, according to the government
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.